<DOC>
	<DOCNO>NCT00098423</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tanespimycin give cytarabine treat patient relapsed refractory acute myeloid leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic myelomonocytic leukemia , myelodysplastic syndrome . Drugs use chemotherapy , tanespimycin cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Tanespimycin may also help cytarabine kill cancer cell make cancer cell sensitive drug . Giving tanespimycin together cytarabine may kill cancer cell .</brief_summary>
	<brief_title>Tanespimycin Cytarabine Treating Patients With Relapsed Refractory Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Chronic Myelogenous Leukemia , Chronic Myelomonocytic Leukemia , Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) ( tanespimycin ) administer cytarabine patient relapse refractory acute myeloid leukemia , acute lymphoblastic leukemia , chronic myelogenous leukemia , chronic myelomonocytic leukemia , high-grade myelodysplastic syndrome . II . Determine toxic effect regimen patient . III . Determine , preliminarily , activity regimen patient . IV . Correlate pharmacokinetics regimen cytochrome p450 3A5 genotype patient . V. Determine effect regimen client proteins vivo ex vivo use leukemic blast patient treat regimen . OUTLINE : This multicenter , dose-escalation study tanespimycin . Patients receive induction therapy comprise cytarabine intravenously ( IV ) continuously day 1-5 tanespimycin IV 1 hour day 3 6 . Patients achieve morphologic complete response incomplete blood count recovery ( CRi ) partial response may eligible receive second induction course therapy day 21 discretion principal investigator . Patients achieve complete response ( CR ) receive 4 course consolidation therapy cytarabine tanespimycin . Consolidation therapy repeat approximately every 60 day absence disease progression unacceptable toxicity . Patients achieve CR remain remission ≥ 6 month may retreat cytarabine tanespimycin ( current dose level maximum tolerate dose [ MTD ] ) time relapse . Cohorts 3-6 patient receive escalate dos tanespimycin MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 3 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia , except acute promyelocytic leukemia ( M3 disease ) , meet 1 follow criterion : Failed achieve complete remission ( CR ) initial induction therapy regimen* First relapse within 1 year initial CR Failed reinduction therapy first second relapse Second third relapse complete ≤ 3 different induction therapy regimens Antecedent hematologic disorder ( myelodysplastic syndrome [ MDS ] , chronic myeloproliferative disease , chronic myelomonocytic leukemia [ CMML ] ) Received prior chemotherapy nonhematologic malignancy Highrisk cytogenetic abnormality ( abnormality chromosome 5 , 7 , 8 , 11 OR ≥ 3 karyotypic abnormality ) Acute lymphoblastic leukemia , meet 1 follow criterion : Failed achieve CR initial induction therapy regimen First relapse within 1 year initial CR Failed reinduction therapy first second relapse Second third relapse complete ≤ 3 different induction therapy regimens Chronic myelogenous leukemia , meet follow criterion : Accelerated OR blast phase ( &gt; 10 % increase blast percentage bone marrow ) Failed prior imatinib mesylate No 1 prior chemotherapy regimen addition imatinib mesylate CMML , meet follow criterion : More 10 % increase blast percentage AND organ infiltration OR impend marrow failure evidence cytopenia No ( 5 ; 12 ) cytogenetics ( unless fail prior trial imatinib mesylate ) Highgrade MDS , define &gt; 10 % blast marrow cellularity ( refractory anemia excess blast transformation ) OR International Prognostic Scoring System MDS prognostic score &gt; 1.5 Not candidate allogenic bone marrow transplantation* relate sibling donor ( i.e. , HLAidentical sibling ) No know standard potentially curative therapy exist capable extend life expectancy No clinical symptom suggest CNS leukemia Performance status ECOG 02 At least 60 day See Disease Characteristics Bilirubin ≤ 1.5 time upper limit normal ( unless attribute underlying disease ) Creatinine clearance ≥ 60 mL/min No New York Heart Association class IIIIV heart failure No myocardial infarction within past year LVEF ≥ 40 % MUGA No cardiac symptom ≥ grade 2 No uncontrolled dysrhythmia require medication No poorly control angina QTc ≤ 450 msec men ≤ 470 msec woman No congenital long QT syndrome No leave bundle branch block No ischemic heart disease within past 6 month No history cardiac toxicity treatment anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine No significant cardiac disease No active uncontrolled infection No history serious allergic reaction egg No known HIV infection AIDS ( without highly active antiretroviral treatment ) DLCO &gt; 80 % No pulmonary symptom ≥ grade 2 No symptomatic pulmonary disease require medication include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Significant pulmonary disease ( e.g. , chronic obstruction/restrictive pulmonary disease ) No oxygen requirement No home oxygen meet medicare requirement No history pulmonary toxicity treatment anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychosis No serious underlie medical condition would preclude study participation No prior allogeneic autologous bone marrow transplantation No concurrent immunotherapy No concurrent biologic agents No concurrent gene therapy See Disease Characteristics Recovered prior chemotherapy At least 48 hour since prior hydroxyurea prevention leukostasis No concurrent chemotherapy At least 48 hour since prior glucocorticoid prevention leukostasis No prior radiotherapy included heart field ( e.g. , mantle ) chest No concurrent radiotherapy No concurrent drug may cause QTc prolongation No concurrent participation another clinical trial involve pharmacologic agent symptom control therapeutic intent No concurrent investigational drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>